logo
Nomad Foods Reports First Quarter 2025 Financial Results

Nomad Foods Reports First Quarter 2025 Financial Results

Strong gross margin expansion helped fuel reinvestment
Retailer destocking & Easter timing offset retail sell-out growth
Recalibrating full year sales, Adjusted EBITDA and Adjusted EPS expectations
WOKING, England, May 8, 2025 /PRNewswire/ -- Nomad Foods Limited (NYSE: NOMD), today reported financial results for the three month period ended March 31, 2025.
Key operating highlights and financial performance for the first quarter 2025, when compared to the first quarter 2024, include:
Management Comments
Stéfan Descheemaeker, Nomad Foods' Chief Executive Officer, stated, 'Our team continued to execute well against our strategic priorities in the first quarter. Our organization delivered another quarter of strong gross margin improvement while continuing to scale our Growth Platforms, strengthen our innovation pipeline and reinvest in our leading brands. We saw slightly positive in-market consumption growth in the first quarter, but faced larger than expected retailer inventory destocking which, when combined with Easter timing, caused our net sales growth to meaningfully lag our retail sell-out. We expect top-line growth to accelerate throughout the remainder of the year, but do not expect to recover the larger than expected destocking related losses incurred in the first quarter. We have tempered our full year revenue expectations as a result. And although we see no direct impact from tariffs at this point in time, the macro environment has become increasingly uncertain and we foresee further increases in some input costs. These dynamics, in combination with the destocking impact in the first quarter, have caused us to lower our full year Adjusted EBITDA expectations while widening our Adjusted EPS guidance range.'
Noam Gottesman, Nomad Foods' Co-Chairman and Founder, commented, 'Nomad Foods has spent the last two years strengthening its overall organization, scaling its innovation pipeline and bolstering both the quantity and quality of its advertising investment while leveraging its strong cash flow to fortify its balance sheet and return cash to shareholders. Quarterly results can be choppy but the Frozen Food category in Europe is healthy, Nomad Food's leading brands are strong and its portfolio remains well positioned for evolving consumer trends. We remain confident in the company's growth potential and believe results for the remainder of 2025 will reflect this.'
First Quarter of 2025 results compared to the First Quarter of 2024
2025 Guidance
The confluence of greater than expected retailer inventory destocking, higher input cost inflation, macro uncertainty and the prioritization of continued reinvestment in its brands and products has caused Nomad Foods to lower its full year revenue and Adjusted EBITDA outlook while widening its Adjusted EPS guidance range at the low-end. For the full year 2025, Nomad Foods now expects organic revenue growth of 0%-2%, versus 1%-3% growth prior, Adjusted EBITDA growth of 0%-2%, versus 2%-4% growth prior and Adjusted EPS of €1.82-€1.89, implying growth of 2-6%, versus its prior Adjusted EPS range of €1.85-€1.89, as the benefit of a lower share count partially offsets the lower Adjusted EBITDA outlook. Based on USD/EUR exchange rate as of May 2, 2025, this translates into 2025 Adjusted EPS of $2.07-$2.15. The Company is also maintaining its full year adjusted free cash flow conversion guidance to 90% or greater.
Conference Call and Webcast
The Company will host a conference call with members of the executive management team to discuss these results today, Thursday, May 8, 2025 at 1:30 p.m. BST (8:30 a.m. Eastern Daylight Time). To participate on the live call listeners in North America may dial +1-844-676-5834 and international listeners may dial +1-412-634-6811. Additionally, there will be a presentation to accompany the conference call and the call is being webcast. Both can be accessed at the Nomad Foods website at www.nomadfoods.com under Investor Relations. A replay of the conference call will be available on the Company website for two weeks following the event and can be accessed by listeners in North America by dialing +1-844-512-2921 and by international listeners by dialing +1-412-317-6671; the replay pin number is 10198025.
Enquiries
Investor Relations Contact
Jason English
[email protected]
Media Contact
Oliver Thomas, Head of Corporate Affairs
[email protected]
About Nomad Foods
Nomad Foods (NYSE: NOMD) is Europe's leading frozen food company. The Company's portfolio of iconic brands, which includes Birds Eye, Findus, iglo, Ledo and Frikom, have been a part of consumers' meals for generations, standing for great tasting food that is convenient, high quality and nutritious. Nomad Foods is headquartered in the United Kingdom. Additional information may be found at www.nomadfoods.com.
Non-IFRS Financial Information
Nomad Foods is presenting Adjusted and Organic financial information, which is considered non-IFRS financial information, for the three months ended March 31, 2025 and for comparative purposes, the three months ended March 31, 2024.
Adjusted financial information for the three months ended March 31, 2025 and 2024 presented in this press release reflects the historical reported financial statements of Nomad Foods, adjusted primarily for, when they occur, share based payment expenses and related employer payroll taxes, non-operating M&A related costs, acquisition purchase price adjustments, exceptional items and foreign currency translation charges/gains.
Adjusted EBITDA is profit or loss for the period before taxation, net financing costs, depreciation and amortization, adjusted to exclude, when they occur, the impacts of exited markets, acquisition purchase price adjustments and exceptional items such as restructuring charges, goodwill and intangible asset impairment charges and other unusual or non-recurring items. In addition, we exclude other adjustments such as the impact of share based payment expenses and related employer payroll taxes, and non-operating M&A related costs, because we do not believe they are indicative of our normal operating costs, can vary significantly in amount and frequency, and are unrelated to our underlying operating performance. The Company believes Adjusted EBITDA provides important comparability of underlying operating results, allowing investors and management to assess operating performance on a consistent basis.
Adjusted EBITDA should not be considered as an alternative to profit/(loss) for the period, determined in accordance with IFRS, as an indicator of the Company's operating performance.
Adjusted Profit for the period is defined as profit for the period excluding, when they occur, the impacts of exited markets, acquisition purchase price adjustments and exceptional items such as restructuring charges, goodwill and intangible asset impairment charges, net financing income/(cost) on amendment of terms of debt, interest cost on tax relating to legacy tax audits, foreign exchange translation gains/(losses), foreign exchange gains/(losses) on derivatives, as well as certain other items considered unusual or non-recurring in nature. In addition, we exclude other adjustments such as the impact of share based payment expenses and related employer payroll taxes, and non-operating M&A related costs, because we do not believe they are indicative of our normal operating costs, can vary significantly in amount and frequency, and are unrelated to our underlying operating performance. The Company believes Adjusted Profit after tax provides important comparability of underlying operating results, allowing investors and management to assess operating performance on a consistent basis.
Adjusted EPS is defined as diluted earnings per share excluding, when they occur, the impacts of exited markets, acquisition purchase price adjustments and exceptional items such as restructuring charges, goodwill and intangible asset impairment charges, net financing income/(cost) on amendment of terms of debt, interest cost on tax relating to legacy tax audits, foreign exchange translation gains/(losses), foreign exchange gains/(losses) on derivatives, as well as certain other items considered unusual or non-recurring in nature. In addition, we exclude other adjustments such as the impact of share based payment expenses and related employer payroll taxes, and non-operating M&A related costs, because we do not believe they are indicative of our normal operating costs, can vary significantly in amount and frequency, and are unrelated to our underlying operating performance. The Company believes Adjusted EPS provides important comparability of underlying operating results, allowing investors and management to assess operating performance on a consistent basis.
Organic revenue growth/(decline) is an adjusted measurement of our operating results. The comparison for the three months ended March 31, 2025 and 2024 presented in this press release takes into consideration only those activities that were in effect during both time periods. Organic revenue growth/(decline) reflects reported revenue adjusted for currency translation and non-comparable trading items such as expansion, acquisitions, disposals, closures, trading day impacts or any other event that artificially impacts the comparability of our results period over period.
Adjustments for currency translation are calculated by translating data of the current and comparative periods using a budget foreign exchange rate that is set once a year as part of the Company's internal annual forecast process.
Adjusted Free Cash Flow – Adjusted free cash flow is the amount of cash generated from operating activities less cash flows related to exceptional items (as described above), non-operating M&A related costs and working capital movements on employer taxes associated with share based payment awards, plus capital expenditure (on property, plant and equipment and intangible assets), net interest paid, proceeds/(payments) on settlement of derivatives where hedge accounting is not applied and payments of lease liabilities. Adjusted free cash flow reflects cash flows that could be used for payment of dividends, repayment of debt or to fund acquisitions or other strategic objectives.
Cash flow conversion is Adjusted Free Cash Flow as a percentage of Adjusted Profit for the period.
Adjusted and Organic non-IFRS financial information should be read in conjunction with the unaudited financial statements of Nomad Foods included in this press release as well as the historical financial statements of the Company previously filed with the SEC.
Nomad Foods believe its non-IFRS financial measures provide an important additional measure with which to monitor and evaluate the Company's ongoing financial results, as well as to reflect its acquisitions. Nomad Foods' calculation of these financial measures may be different from the calculations used by other companies and comparability may therefore be limited. The Adjusted and Organic financial information presented herein is based upon certain assumptions that Nomad Foods believes to be reasonable and is presented for informational purposes only and is not necessarily indicative of any anticipated financial position or future results of operations that the Company will experience. You should not consider the Company's non-IFRS financial measures an alternative or substitute for the Company's reported results and are cautioned not to place undue reliance on these results and information as they may not be representative of our actual or future results as a Company.
Please see on pages 7 to 10, the non-IFRS reconciliation tables attached hereto and the schedules accompanying this release for an explanation and reconciliation of the Adjusted and Organic financial information to the most directly comparable IFRS measure. The Company is unable to reconcile, without unreasonable efforts, Organic Growth, Adjusted EBITDA and Adjusted EPS guidance to the most directly comparable IFRS measure.
Nomad Foods Limited
Reconciliation of Non-IFRS Financial Measures
(In € millions, except per share data)
The following table reconciles adjusted financial information for the three months ended March 31, 2025 to the reported results of Nomad Foods for such period.
Nomad Foods Limited
Reconciliation of Non-IFRS Financial Measures (continued)
The following table reconciles adjusted financial information for the three months ended March 31, 2024 to the reported results of Nomad Foods for such period.
Nomad Foods Limited
Reconciliation of Non-IFRS Financial Measures (continued)
The following table reconciles Adjusted EBITDA to the reported results of Nomad Foods for each period.
Nomad Foods Limited
Reconciliation of Non-IFRS Financial Measures (continued)
Reconciliation from reported to organic revenue growth/(decline)
The following table is a reconciliation of reported revenue growth to Organic Revenue Growth for the three month period ended March 31, 2025.
Forward-Looking Statements
Forward-Looking Statements and Disclaimers
Certain statements in this announcement are forward-looking statements which are based on the Company's expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts, including the Company's expectations regarding (i) its future operating and financial performance, including its 2025 guidance with respect to organic revenue growth, Adjusted EBITDA growth, adjusted free cash flow conversion, Adjusted EPS, and Adjusted EPS growth; (ii) top-line growth for the remainder of 2025 and ability to recover larger than expected losses in the first quarter, (iii) macro-economic factors, including the impact of tariffs, (iv)its ability to generate superior shareholder returns; (v) its cash generation, growth and success in 2025 and beyond; and (vi) its portfolio's ability to remain well positioned for consumer trends.
These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including: (i) the Company's ability to effectively mitigate factors that negatively impact its supply of raw materials, including the conflict in Ukraine and climate-related factors beyond the Company's control; (ii) the Company's ability to successfully mitigate inflationary changes in the market; (iii) the Company's ability to successfully identify suitable acquisition targets and adequately evaluate the potential performance of such acquisition targets; (iv) the Company's ability to successfully implement its strategies (including its M&A strategy) and strategic initiatives and to recognize the anticipated benefits of such strategic initiatives; (v) innovations introduced to the markets and the Company's ability to accurately forecast the brands' performance; (vi) the Company's ability to effectively compete in its markets; (vii) changes in consumer preferences, such as meat substitutes, and the Company's failure to anticipate and respond to such changes or to successfully develop and renovate products; (viii) the effects of reputational damage from unsafe or poor quality food products; (ix) the risk that securities markets will react negatively to actions by the Company; (x) the adequacy of the Company's cash resources to achieve its anticipated growth agenda; (xi) increases in operating costs, including labor costs, and the Company's ability to manage its cost structure; (xii) fluctuations in the availability of food ingredients and packaging materials that the Company uses in its products; (xiii) the Company's ability to protect its brand names and trademarks; (xiv) the Company's ability to prevent, or remediate, any future cybersecurity incidents; (xv) loss of the Company's financial arrangements with respect to receivables factoring; (xvi) the loss of any of the Company's major customers or a decrease in demand for its products; (xvii) economic conditions that may affect the Company's future performance including exchange rate fluctuations; (xviii) the Company's ability to successfully interpret and respond to key industry trends and to realize the expected benefits of its responsive actions; (xix) the Company's failure to comply with, and liabilities related to, environmental, health and safety laws and regulations; (xx) changes in applicable laws or regulations; (xxi) the Company's ability to remediate any material weaknesses in its internal control over financial reporting; and (xxii) the other risks and uncertainties disclosed in the Company's public filings and any other public disclosures by the Company. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company does not undertake any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
No Offer or Solicitation
This release and referenced conference call is provided for informational purposes only and does not constitute an offer to sell, or an invitation to subscribe for, purchase or exchange, any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance, exchange or transfer of the securities referred to in this press release in any jurisdiction in contravention of applicable law.
The release, publication or distribution of this announcement in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this announcement is released, published or distributed should inform themselves about and observe such restrictions.
View original content to download multimedia: https://www.prnewswire.com/news-releases/nomad-foods-reports-first-quarter-2025-financial-results-302449268.html
SOURCE Nomad Foods Limited
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Buy or Sell UNH Stock Ahead of Its Upcoming Earnings?
Buy or Sell UNH Stock Ahead of Its Upcoming Earnings?

Forbes

time11 minutes ago

  • Forbes

Buy or Sell UNH Stock Ahead of Its Upcoming Earnings?

CHONGQING, CHINA - JULY 27: In this photo illustration, a smartphone displays the logo of ... More UnitedHealth Group Incorporated (NYSE: UNH), a leading American healthcare and insurance company, in front of a screen showing the company's latest stock market chart on July 27, 2025 in Chongqing, China. (Photo illustration by) UnitedHealth (NYSE:UNH) is set to release its earnings on Tuesday, July 29, 2025. Analyzing the past five years of data, UNH stock has exhibited a trend of positive one-day returns after earnings announcements in 53% of cases. The median one-day gain was 4.0%, with the highest single-day increase reaching 7.2%. While the actual results in comparison to consensus estimates will be vital, comprehending these historical patterns can offer an edge for event-driven traders. There are two primary strategies to leverage this information: Analysts' consensus estimates for the forthcoming quarter anticipate earnings of $4.94 per share on revenue of $111.6 billion. This stands in contrast to last year's quarter earnings of $6.80 per share on revenues of $98.86 billion. The expected contraction in profit margins, as indicated by the lower EPS estimate despite higher revenue, is mainly attributed to escalating medical costs. From a fundamental standpoint, UnitedHealth Group has a current market capitalization of roughly $267 billion. Over the past twelve months, the company generated $410 billion in revenue, reporting $33 billion in operating profits and a net income of $22 billion, showcasing robust operational profitability. That being said, if you're looking for potential upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — having outperformed the S&P 500 and produced returns exceeding 91% since its inception. See earnings reaction history of all stocks UnitedHealth's Historical Odds Of Positive Post-Earnings Return Here are some insights on one-day (1D) post-earnings returns: Additional data for recorded 5-Day (5D) and 21-Day (21D) returns post earnings are detailed along with the statistics in the table below. UNH 1D, 5D, and 21D Post Earnings Return Correlation Between 1D, 5D, and 21D Historical Returns A relatively less risky approach (although not effective if the correlation is low) is to comprehend the correlation between short-term and medium-term returns following earnings, identify a pair that has the highest correlation, and execute the appropriate trade. For instance, if 1D and 5D reveal the highest correlation, a trader can position themselves "long" for the next 5 days if the 1D post-earnings return is positive. Below are some correlation statistics derived from the 5-year and 3-year (more recent) history. It is worth noting that the correlation 1D_5D refers to the correlation between 1D post-earnings returns and subsequent 5D returns. UNH Correlation Between 1D, 5D and 21D Historical Returns Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (combination of all 3, the S&P 500, S&P mid-cap, and Russell 2000), delivering strong returns for investors. Additionally, if you desire upside with a more stable experience than an individual stock like UnitedHealth, consider the High Quality portfolio, which has outperformed the S&P and achieved >91% returns since its launch.

The Best Berkshire Hathaway Stock to Invest $1,000 in Right Now
The Best Berkshire Hathaway Stock to Invest $1,000 in Right Now

Yahoo

timean hour ago

  • Yahoo

The Best Berkshire Hathaway Stock to Invest $1,000 in Right Now

Key Points American Express only issues its cards to lower-risk consumers. As both a card issuer and a bank, it's well-insulated from interest rate swings. Its stock is still reasonably valued relative to its growth potential. 10 stocks we like better than American Express › Many investors follow Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) $293.8 billion portfolio because those stocks were approved by Warren Buffett himself. Even though Buffett plans to step down as Berkshire's chief executive officer this year, his successor, Greg Abel, probably won't dramatically shake up those top holdings. One of those top investments is American Express (NYSE: AXP), which accounts for 15.9% of Berkshire's portfolio and is the company's second largest holding after Apple (NASDAQ: AAPL). Buffett initially accumulated shares of American Express in 1964 through a partnership before his full takeover of Berkshire Hathaway in 1965, and he significantly increased Berkshire's position in the company in 1991. Today, Berkshire owns 21.6% of the entire company. Berkshire hasn't bought or sold any shares of American Express since 2012. Let's see why Buffett considered it to be such a reliable long-term investment -- and why it's a great place to park a fresh $1,000 investment, even as the market hovers near its all-time highs. It's an exclusive club for higher-income consumers American Express is often considered a credit card company like Visa (NYSE: V) and Mastercard (NYSE: MA), but it operates a completely different business model. Visa and Mastercard don't issue any cards or run their own banks. They only partner with banks and other financial institutions to issue co-branded cards and handle those accounts. Visa and Mastercard only generate revenue by charging merchants "swipe fees" for every transaction that runs through their card-processing networks. American Express is both a card issuer and a bank. Since it needs to support its own cards with its own balance sheet, it only offers those cards to lower-risk, higher-income consumers. That exclusivity limits its growth, but it also reduces its credit risk and boosts its appeal as a status symbol. That's why Buffett said you "can't create another American Express" in a Bloomberg interview in late 2022, and why he repeatedly praised its wide competitive moat. At the end of 2024, only 0.8% of American Express' consumer and small business loans were delinquent by more than 30 days, compared to a ratio of 1% at the end of 2023. It also only allocated 8% of its total revenue (net of interest expense) to its credit loss provisions in 2024. It's well-insulated from inflation and interest rate swings Since American Express is both a card issuer and a bank, it's better insulated from inflation and interest rate swings than Visa and Mastercard. Rising rates can reduce the swipe fees at all three companies as consumers curb spending. However, higher rates also boost the net interest income of American Express' banking segment by attracting more deposits and collecting higher interest payments on its loans. That balance makes it a good all-weather stock to hold, regardless of where interest rates go in the future. Stable growth rates at a reasonable valuation From 2014 to 2024, American Express' revenue (net of interest expense) and diluted earnings per share (EPS) grew at a compound annual growth rate (CAGR) of 7% and 10%, respectively. It also bought back nearly a third of its shares during the past 10 years, and it's paid continuous dividends for nearly five decades. It achieved that steady growth even as the pandemic, inflation, rising interest rates, geopolitical conflicts, and other macro headwinds rattled the global economy. From 2024 to 2027, analysts expect its revenue and diluted EPS to grow at CAGRs of 8% and 12%, respectively. That growth should be driven by higher spending among affluent customers (especially for travel and leisure), the rollout of more travel-related perks, higher fee-based revenue from its premium cards, and its overseas expansion. It's cheap relative to its growth potential American Express' stock has already gained about 290% during the past decade, but it still looks like a bargain at 20 times next year's earnings. For reference, Visa and Mastercard trade at 28 times and 35 times next year's earnings, respectively. American Express won't ever be an exciting growth play, but it's a great stock to buy, hold, and forget. Do the experts think American Express is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did American Express make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,041% vs. just 183% for the S&P — that is beating the market by 858.71%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 American Express is an advertising partner of Motley Fool Money. Leo Sun has positions in Apple and Berkshire Hathaway. The Motley Fool has positions in and recommends Apple, Berkshire Hathaway, Mastercard, and Visa. The Motley Fool has a disclosure policy. The Best Berkshire Hathaway Stock to Invest $1,000 in Right Now was originally published by The Motley Fool Sign in to access your portfolio

Goldman Sachs Maintains a Hold on Bristol-Myers Squibb (BMY)
Goldman Sachs Maintains a Hold on Bristol-Myers Squibb (BMY)

Yahoo

timean hour ago

  • Yahoo

Goldman Sachs Maintains a Hold on Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman Sachs analyst Asad Haider maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) with a $56.00 price target, basing the rating on the company's current market position. A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. Haider stated that Bristol-Myers Squibb Company (NYSE:BMY) is anticipated to release mixed results for the upcoming quarter. While foreign exchange rates may have some positive impact on the earnings, potential negative effects from recent deals not fully accounted for in current earnings projections, and challenges at the product level are cause for concern. The analyst further said that Bristol-Myers Squibb Company's (NYSE:BMY) stock has remained stable within a narrow range despite it trading at a lower multiple compared to its peers and prior strong quarterly results. He reasoned that this stability is partially because of investors anticipating significant clinical trial outcomes, especially the Phase-3 ADEPT-2 trial for Cobenfy in Alzheimer's psychosis. The Hold rating thus suggests the need for clarity regarding these clinical developments as they may prove critical for future stock movement. Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience. While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store